Wpływ przezcewnikowego zamknięcia przetrwałego otworu owalnego u pacjentów z udarem kryptogennym na zaburzenia rytmu serca- obserwacja 3-miesięczna by Wittczak, Andrzej et al.
8 www.journals.viamedica.pl/folia_cardiologica
Folia Cardiologica 2021 
vol. 16, no. 1, pages 8–15 
DOI: 10.5603/FC.2021.0003 
Copyright © 2021 Via Medica
ISSN 2353–7752
ORIGINAL PAPER/PRACA ORYGINALNA
Address for correspondence: Agata Bielecka-Dąbrowa MD, PhD, FESC, FHFA, Associate Professor of Cardiology, Pracownia Niewydolności Serca,  
Klinika Kardiologii i Wad Wrodzonych Dorosłych, Instytut Centrum Zdrowia Matki Polki, ul. Rzgowska 281/289; 93–338 Łódź, Poland,  
phone +48 42 271 15 97, fax +48 42 271 15 91, e-mail: agatbiel7@poczta.onet.pl
Transcatheter closure of patent foramen ovale  
in patients with cryptogenic stroke: impact on arrhythmia  
in 3 months follow-up
Wpływ przezcewnikowego zamknięcia przetrwałego otworu owalnego u pacjentów 
z udarem kryptogennym na zaburzenia rytmu serca — obserwacja 3-miesięczna
Andrzej Wittczak1, 2●iD, Marek Maciejewski3, Tomasz Moszura4●iD, Paweł Dryżek4,  
Maciej Banach5, 6●iD, Agata Bielecka-Dąbrowa5, 6●iD
1Students’ Scientific Group at the Department of Cardiology and Congenital Diseases of Adults,  
Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland 
2Medical University of Lodz, Łódź, Poland 
3Department of Cardiology and Congenital Diseases of Adults, Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland 
4Department of Cardiology, Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland 
5Heart Failure Unit, Department of Cardiology and Congenital Diseases of Adults,  
Polish Mother’s Memorial Hospital Research Institute, Łódź, Poland 
6Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Łódź, Poland
Abstract
Introduction. Patent foramen ovale (PFO) is a common abnormality, occurring in about 25% of the population. Percuta-
neous PFO closure is recommended for selected patients in the prevention of recurrent thromboembolic events. Although 
transcatheter closure of PFO is recognized as a safe procedure, potential complications, such as atrial fibrillation, may 
occur. The purpose of this study was to assess the prevalence of arrhythmia in patients before and after PFO closure.
Material and methods. The authors retrospectively reviewed the medical records of 45 patients [median age 45 (in-
terquartile range 35–61) years; 80% female] who underwent percutaneous PFO closure. 24-hour Holter electrocardio-
grams (ECG) were done both before and 3 months after the procedure in 21 patients [median age 49 (38–65) years; 
81% female], however, data of predominant underlying rhythm was available for all 45 patients.
Results. There were no statistically significant differences in maximal and minimal heart rate, number of supraventri-
cular and ventricular extrasystolic beats, pauses, episodes of supraventricular and ventricular tachycardia in patients 
before and after the PFO closure procedure. Median average heart rate was significantly higher before the procedure 
[70 (67–78) bpm vs. 69 (62–77) bpm; p = 0.03]. Among the 45 patients, one had a history of paroxysmal atrial fibril-
lation (AF) before the procedure. During the follow-up, no AF was found.
Conclusions. Transcatheter closure of PFO did not affect arrhythmias observed in 24-hour Holter ECG monitoring of 
the patients. The procedure has a low risk of complications if performed in selected patients by an adequately trained 
operator in an experienced centre.
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ones (such as residual leakage and atrial arrhythmias) with 
an incidence of 7.9% [2]. Implantation of a PFO occluder 
significantly increases the likelihood of atrial fibrillation. In 
a meta-analysis of randomized control trials, a 4.6% inci-
dence was reported after 3.8 years of follow-up [9]. Furt-
hermore, arrhythmia after the PFO closure procedure can 
be manifested by atrial additional beats or, less often, by 
transient atrioventricular conduction disturbances [2].
Despite the increasing popularity of the procedure, 
there have been only several studies on complications 
of the PFO closure procedure thus far and only a few on 
arrhythmic ones. The purpose of this study was to assess 




We retrospectively analyzed the data of 45 patients who 
underwent percutaneous PFO closure in the Department 
of Cardiology and Congenital Diseases of Adults, Polish 
Mother’s Memorial Hospital Research Institute in Lodz 
between June 8, 2017, and February 19, 2020. All patients 
who were qualified for the procedure had confirmed brain 
ischemic lesions in neuroradiological imaging and high-
-risk PFO detected in transesophageal echocardiography 
(TEE). Almost all procedures were performed with the use 
of Occlutech Figulla Flex II PFO Occluder (Occlutech GmbH, 
Jena, Germany), in two cases Occlutech Figulla Flex II ASD 
Occluder was used due to PFO anatomy. All patients had 
a follow-up hospitalization about 3 months after their 
procedure.
The study was performed in accordance with the guideli-
nes and regulations approved by the Bioethics Commission 
of the Polish Mother’s Memorial Hospital Research Institute 
in Lodz and approval from this commission was obtained.
Data collection
All data were collected from the medical records of the De-
partment of Cardiology and Congenital Diseases of Adults. 
A variety of demographic data was collected including age, 
sex, body weight, height, body mass index (BMI), body sur-
face area (BSA), systolic (SBP) and diastolic blood pressure 
(DBP) at admission and heart rate (HR) at admission. The 
authors searched for a history of heart failure, coronary 
artery disease, hypertension, paroxysmal and permanent 
atrial fibrillation, diabetes mellitus, hypercholesterolemia, 
deep vein thrombosis, obesity, migraine along with a history 
of smoking and excessive alcohol consumption.
We studied the results of examinations performed du-
ring patients’ hospitalizations. All patients underwent con-
trast TEE before the procedure. From TEE reports parame-
ters associated with PFO were obtained. These included 
Introduction
The foramen ovale is an anatomical structure, which 
connects the right and left atrium in the fetal circulation. 
After birth, it physiologically closes by age two, however, it 
remains patent in about 25% of the population [1]. Due to 
patent foramen ovale (PFO) commonness, its presence in 
itself is not considered a pathology [2]. Nevertheless, an 
association between PFO and cryptogenic stroke has been 
found and proved [3, 4].
Ischemic strokes account for over 80% of all strokes 
and are a result of obstruction of arteries supplying the 
brain [5]. In as many as 25% of ischemic stroke cases, 
the cause of ischemia is unknown; in such cases, the term 
cryptogenic stroke is used. Most of the cryptogenic strokes 
are considered embolic [6]. In 2014 the term of embolic 
stroke of undetermined source (ESUS) was formed to de-
scribe patients with a non-lacunar ischemic stroke and no 
specific cause of stroke. The set criteria to define ESUS 
enabled the conduction of randomized controlled trials in 
this population [7].
PFO is one of the main pathologies etiologically asso-
ciated with ESUS. The presumed mechanism of ischemic 
stroke in patients with PFO is a paradoxical embolization. 
The embolism is caused by the infiltration of the venous 
thrombus from the right to the left atrium under hemody-
namic conditions where the PFO is opened [8]. The trans-
catheter PFO closure is a percutaneous procedure per-
formed for the prevention of recurrent strokes in patients 
with a history of cryptogenic stroke and PFO. It was first 
introduced in 1992; since then the efficacy and safety of 
closing PFO have been examined in several studies. De-
spite the initially disappointing results of randomized trials 
(such as CLOSURE 1 or PC Trial), subsequent studies (e.g. 
DEFENSE-PFO) confirmed the effectiveness of interventio-
nal therapy in high-risk PFO patients [2]. In 2019 a joint 
task force of the European Association of Percutaneous 
Cardiovascular Interventions (EAPCI) and 8 other European 
societies published a position paper on the management 
of patients with PFO. The authors stated that the trans-
catheter PFO closure should be performed ‘in carefully 
selected patients aged from 18 to 65 years with a confir-
med cryptogenic stroke, transient ischemic attack (TIA), 
or systemic embolism and an estimated high probability 
of a causal role of the PFO as assessed by clinical, anato-
mical and imaging features’ [9].
The transcatheter PFO closure is considered as an ef-
fective and safe procedure. According to the European po-
sition paper, the primary technical success of PFO closure 
approaches 100% with complete closure seen in 93–96% 
at one year [9]. The perioperative complications could be 
divided into major ones (such as device embolization or 
device thrombosis) with an incidence of 1.5% and minor 
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the presence of right-to-left shunt during the Valsalva ma-
noeuvre, dimensions of the PFO canal and distances of the 
edge of the canal from the aorta, mitral ring and superior 
vena cava. It was checked whether atrial septal aneurysm 
(ASA), Chiari network or Eustachian valve were identified. 
During follow-up hospitalization, all patients had transtho-
racic echocardiography (TTE), in which the placement of 
a device and closure effect was assessed.
24-hour Holter electrocardiograms (ECGs) were done 
both before and 3 months after the procedure in 21 of 
45 patients. Reports from follow-up 12-lead ECGs were 
available in all cases, therefore data of predominant un-
derlying rhythm was available for all 45 patients.
Statistical analysis
The STATISTICA 13.1 software package (StatSoft, Poland) 
was used for analysis. A p-value of < 0.05 was considered 
significant. The Shapiro-Wilk test was used to assess the 
normality of distribution. Nominal variables were presented 
as numbers and percentages. Continuous variables were 
expressed as mean and standard deviation (variables 
with normal distribution) or median with the first and third 
quartiles (variables with nonnormal distribution). Student’s 
t-test was used to compare continuous variables with 
normal distribution and with homogeneity of variance. 
For nonnormally distributed variables, the Mann-Whitney 
U test was used. The dichotomous data were analyzed by 
the chi-squared test, chi-squared test with Yates correction 
or Fisher exact test. Wilcoxon signed-rank test was used to 
assess the differences of continuous Holter ECG parame-
ters from tests done before and 3 months after the PFO 
closure procedure. Collected data were analyzed for all 45 
patients and the 21-patients subgroup, for whom findings 
of Holter ECG done both before and 3 months after the 
procedure were available.
Results
Both in the group of 45 patients as well as in the 
21-patients subgroup, females made up about 80% of 
patients, with a median age of 45 (35–61) years in the 
first group and 49 (38–65) years in the second (Table 1). 
Table 1. Basic characteristics of patients
Parameter PFO closure 
(N = 45)
PFO closure: Holter ECG done both before 
and 3 months after the procedure (N = 21)
p
Gender (female) [N, %] 36 (80%) 17 (81%) 0.81
Age [years] 45 (35–61) 49 (38–65) 0.28
Body mass [kg] 66 (58–79) 66 (58–79) 0.94
Height [m] 1.67 ± 0.093 1.66 ± 0.091 0.69
BMI [kg/m2] 24.57 ± 3.69 24.83 ± 3.78 0.8
BSA [m2] 1.72 (1.59–1.95) 1.72 (1.62–1.95) 0.96
SBP at admission [mm Hg] 124.87 ± 15.19 125.19 ± 17.52 0.94
DBP at admission [mm Hg] 76.62 ± 11.27 74.1 ± 11.18 0.4
HR at admission [/min] 70 (64–78) 70 (60–70) 0.35
Hypertension [N, %] 13 (29%) 7 (33.33%) 0.94
Heart failure [N, %] 2 (4.4%) 1 (4.76%) 0.56
Coronary artery disease [N, %] 2 (4.4%) 2 (9.52%) 0.8
Diabetes mellitus [N, %] 0 0 –
Hypercholesterolemia [N, %] 27 (60%) 14 (66.7%) 0.8
Deep vein thrombosis [N, %] 2 (4.4%) 1 (4.76%) 0.56
Smoking [N, %] 10 (22.22%) 7 (33.33%) 0.51
Excessive alcohol use [N, %] 1 (2.22%) 1 (4.76%) 0.83
Obesity [N, %] 2 (4.4%) 1 (4.76%) 0.56
Migraine [N, %] 9 (20%) 5 (23.81%) 0.98
Paroxysmal AF [N, %] 1 (2.22%) 1 (4.76%) 0.83
Permanent AF [N, %] 0 0 –
Nominal variables were presented as numbers and percentages. For continuous variables with non-normal distribution median values with the first and third quartiles are given. For parameters with normal 
distribution mean values ± standard deviation (SD) are given; PFO — patent foramen ovale; ECG — electrocardiogram; BMI — body mass index; BSA — body surface area; SBP — systolic blood pressure;  
DBP — diastolic blood pressure; HR — heart rate; AF — atrial fibrillation
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About 30% of patients had a history of hypertension and 
about 60% of hypercholesterolemia. In the group of all 
45 patients, 22% admitted to smoking. Interestingly, as 
many as 20% of patients in both groups had a history of 
migraines. Only one patient had a history of paroxysmal 
atrial fibrillation before the procedure and none of the 
patients had a diagnosis of permanent atrial fibrillation 
(AF). In the statistical analysis, there were no significant 
differences in the basic characteristics’ parameters be-
tween the two groups.
Table 2 shows the findings from transesophageal echo-
cardiography. Right-to-left shunt during the Valsalva man-
euver was identified in all patients. In the group of 45 pa-
tients, the median length of the PFO canal was 7 (5–11) 
mm and the median diameter was 4 (3–5) mm [in the 
21-patient subgroup the values were 8 (5–11) mm and 
4 (3–4) mm, respectively]. In the first group, the median 
distance of the edge of the PFO canal from the aorta was 
7 (5–8) mm; from the mitral ring — 13 (12–15) mm; from 
the superior vena cava — 13 (12–17) mm. None of the pa-
tients had a Chiari network, but in 3 cases an Eustachian 
valve was discovered. 12 patients (26.67%) had an ASA. 
In the statistical analysis, there were no significant diffe-
rences in transesophageal echocardiography parameters 
between the two groups.
Table 3 shows the findings in 24-hour Holter ECG done 
before and 3 months after the procedure (N = 21 pa-
tients). Before the procedure, one patient had atrial fi-
brillation; the other 20 patients (95%) had sinus rhythm. 
After the procedure, all patients had sinus rhythm. The-
re were no statistically significant differences in minimal 
and maximal heart rate, the number of supraventricular 
and ventricular extrasystolic beats, the number of pauses 
over 2 seconds, the number of episodes of supraventricu-
lar and ventricular tachycardia in patients before and af-
ter the PFO closure procedure. Only the median average 
heart rate was significantly higher before the procedure 
[70 (67–78) bpm vs. 69 (62–77) bpm; p = 0.03]. There 
were no traces of atrioventricular conduction disturban-
ces in the Holter ECG reports.
12-lead ECG reports of the other 24 patients (patients 
who did not have Holter ECG done before and after the 
procedure) showed that all had sinus rhythm and no ab-
normalities in ECG were identified.
Transthoracic echocardiography done in all patients 
during a follow-up hospitalization showed that the patent 
foramen ovale was successfully closed in all cases.
Discussion
The results of this study revealed that transcatheter closu-
re of PFO did not affect arrhythmias observed in 24-hour 
Holter ECG monitoring of the patients 3 months after the 
procedure. During the follow-up, no atrial fibrillation was 
found and Holter ECG arrhythmia parameters (such as the 
number of supraventricular and ventricular extrasystolic 
beats) from before and after the procedure were not sig-
nificantly different.
The mere presence of patent foramen ovale does not 
appear to be significantly associated with cardiac arrhyth-
mias [10]. Atrial arrhythmias, however, are known com-
plications of percutaneous PFO closure [2, 9]. In a heart 
with PFO, the fast pathway of atrial conduction from the 
sinoatrial (SA) node to the compact atrioventricular (AV) 
Table 2. Findings in transesophageal echocardiography
Parameter PFO closure 
(N = 45)
PFO closure: Holter ECG done both before 
and 3 months after the procedure (N = 21)
p
Right-to-left shunt during the Val-
salva manoeuvre [%]
100 100 –
Length of PFO canal [mm] 7 (5–11) 8 (5–11) 0.93
Diameter of PFO canal [mm] 4 (3–5) 4 (3–4) 0.6
Distance of the edge of the canal 
from aorta [mm]
7 (5–8) 6.5 (5–8) 0.44
Distance of the edge of the canal 
from mitral ring [mm]
13 (12–15) 13.5 (12–15.5) 0.57
Distance of the edge of the canal 
from superior vena cava [mm]
13 (12–17) 13 (11.5–16.5) 0.66
Chiari network [N, %] 0 0 –
Eustachian valve [N, %] 3 (6.67%) 0 0.55
Atrial septal aneurysm [N, %] 12 (26.67%) 8 (38.1%) 0.51
Nominal variables were presented as numbers and percentages. Continuous variables were expressed as median values with the first and third quartiles; PFO — patent foramen ovale; ECG — electrocardiogram
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node typically courses along the anterior margins of a pa-
tent foramen ovale. Furthermore, the superior margins 
of a patent foramen ovale include Bachmann’s bundle, 
which is considered the main pathway of interatrial con-
duction. Therefore, it is intuitive to assume that some 
direct mechanical irritation or injury to these structu-
res may occur after percutaneous PFO closure [11–13]. 
Several pathophysiological mechanisms of procedure-
-induced arrhythmias are suggested in the literature. 
These include mechanical irritation of atrial structures, 
postprocedural inflammatory reaction and a direct im-
pact of PFO occluder on atrial electrophysiology (inflam-
mation and scarring around the closure device can lead 
to anisotropic conduction and macro-reentry around the 
occluder) [9, 10, 14].
AF is one of the most frequent undesirable events fol-
lowing transcatheter percutaneous closure of PFO [9]. In 
a meta-analysis by Turc et al., the authors analyzed data 
from all available randomized controlled trials (RCTs), which 
compared PFO closure, anticoagulation, and antiplatelet 
therapy for the prevention of stroke recurrence in patients 
with PFO-associated cryptogenic stroke. The study, which 
included 3560 patients enrolled in 6 RCTs, revealed that 
PFO closure is superior to antithrombotic therapy, but is 
associated with an increased risk of atrial fibrillation. The 
pooled incidence of new-onset AF per 100 patients trea-
ted was 4.56 [95% confidence interval (CI) 3.58–5.63]. 
The authors concluded that future studies will have to as-
sess the clinical relevance of atrial fibrillation induced by 
PFO closure [15].
The type of PFO closure device may play a role in 
the risk of postprocedural AF. For example, in the Clo-
sure trial, the use of the Starflex (NMT Medical, USA) 
device was associated with a significant increase in 
Table 3. Findings in 24-hour Holter electrocardiogram done before and 3 months after the procedure (N = 21)
Parameter Before procedure After procedure p
Sinus rhythm [N, %] 20 (95%) 21 (100%) > 0.99
HR min [/min] 51 (45–57) 50 (45–55) 0.54
HR max [/min] 115 (102–127) 109 (100–128) 0.4
Average HR [/min] 70 (67–78) 69 (62–77) 0.03
Pauses > 2 s [N] 0 0 –
ExSV [N] 16 (4–86) 18 (5–51) 0.94
Episodes of SVT [N] 0 0 –
ExV [N] 3 (0–134) 8 (0–141) 0.79
Episodes of VT [N] 0 0 –
Nominal variables were presented as numbers and percentages. Continuous variables were expressed as median values with the first and third quartiles; HR — heart rate; ExSV — number of supraventricular 
extrasystolic beats; SVT — supraventricular tachycardia; ExV — number of ventricular extrasystolic beats; VT — ventricular tachycardia
postprocedural AF [16]. In a study by Gevorgyan Fle-
ming et al., the authors compared a residual shunt rate 
and complications associated with six different devices 
used for PFO closure: Amplatzer Cribriform, Amplatzer 
ASO (AGA Medical Corp., USA), Amplatzer PFO (Abbott 
Vascular, USA), Gore Cardioform, Gore Helex (Gore Me-
dical, USA), CardioSEAL (NMTMedical, USA). A total of 
467 patients were retrospectively enrolled in the study 
and 320 of them received a quantitative assessment of 
right-to-left shunting both before and after the PFO closu-
re. The highest closure rate was achieved with the Gore 
Cardioform device (100%, N = 104), the lowest — Amplat-
zer PFO (85%, N = 33). Atrial fibrillation was the most com-
mon significant adverse event. The highest AF incidence 
of 13% was identified in patients with Gore Cardioform 
device, while in patients with Gore Helex and Amplatzer 
PFO it was only 4% [17]. In the study centre, Occlutech 
(Jena, Germany) devices are used. The company launched 
their first occluder in 2003 and their current third-gene-
ration device, available since October 2011, is called Fi-
gulla Flex II [18]. Several studies have been conducted 
to evaluate the efficacy and safety of this device. Neuser 
et al. [18] retrospectively studied the medical records of 
57 patients who underwent the PFO closure with the Fi-
gulla Flex II PFO device. The closure was sufficient with 
no residual right-to-left shunt in 94.4% of all patients at 
6 months post-implantation. One patient was diagnosed 
with paroxysmal atrial fibrillation [18]. A study by Hildick-
-Smith et al. prospectively enrolled 100 patients who un-
derwent the PFO closure with the same device. During 
a six-month follow-up, one case of new-onset atrial fibril-
lation was detected [19]. Trabattoni et al. [20] compared 
the acute and 12-month results of percutaneous closure 
of PFO with Figulla Flex II and Amplatzer PFO. The study 
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showed that both primary technical success and results 
at a 12-month follow-up were comparable between the 
two groups. AF was detected in 4 patients from the Am-
platzer PFO group and in 1 from the Figulla group [20]. 
In the presented study, 43 procedures were performed 
with the use of Figulla Flex II PFO Occluder and 2 with 
the use of Figulla Flex II ASD Occluder, due to PFO ana-
tomy. One patient had a history of paroxysmal atrial fi-
brillation before the procedure, but during the follow-up, 
no episode of AF was found.
Arrhythmias after PFO closure may also be manifested 
by atrial additional beats or atrioventricular conduction 
disturbances [2]. Nevertheless, the incidence of symp-
tomatic postprocedural arrhythmias other than atrial fi-
brillation seems to be low. In the last four randomized 
clinical trials regarding PFO closure, a total of 1210 pa-
tients underwent the procedure (RESPECT — 499 pa-
tients; CLOSE — 238 patients; REDUCE — 413 patients; 
DEFENSE-PRO — 60 patients). Arrhythmic complications 
of the PFO closure in these studies were as follows: in 
RESPECT — 2 cases of AF, 1 case of atrial flutter (AFL) 
and 1 case of nonsustained ventricular tachycardia; in 
CLOSE — 10 cases of AF, 1 case of AFL, 1 case of atrio-
ventricular block and 5 cases of (unspecified) tachy-
arrhythmia; in REDUCE — 28 cases of AF and 1 case of 
AFL; in DEFENSE-PRO — 2 cases of AF. These numbers 
show that postprocedural arrhythmias other than AF/AFL 
in these patients were rare [21–24].
We found one study, which compared findings in 
Holter ECG monitoring from before and after the PFO 
closure. Ateş et al. evaluated the effect of PFO closure 
in 47 patients, using 24-hour Holter ECG monitoring and 
magnetic resonance imaging (MRI). Amplatzer PFO oc-
cluder and Occlutech Figulla PFO occluder were used in 
34 and 13 patients, respectively. 4 patients (8.5%) had 
occasional supraventricular extrasystolic beats (ExSV) 
and 3 patients (6.3%) had occasional ventricular extra-
systolic beats (ExV) before the procedure. After the PFO 
closure, occasional ExSVs were detected in 2 patients 
(4.2%), frequent ExSVs (defined as > 2000 beats/day) 
also in 2 patients, occasional ExVs in 1 patient (2.1%), 
frequent ExVs (defined as > 30 beats/h) also in 1 patient 
and type 1 atrioventricular block in 1 patient (2.1%). No 
atrial fibrillation, atrial flutter or atrial tachycardia were 
detected. Overall, the incidence of arrhythmia did not sta-
tistically increase after the procedure (p = 0.917) [25]. 
The presented study similarly showed that Holter ECG 
arrhythmia parameters from before and after the proce-
dure were not significantly different.
Limitations of the study
There are several limitations to this study. These include 
its retrospective nature and the fact that data was collec-
ted only in one centre and was not compared to a control 
group. Furthermore, only follow-up from 3 months after the 
procedure was available. Finally, only 21 patients had Holter 
ECG done both before and after the procedure.
Conclusions
This study revealed that in the study patients the percuta-
neous PFO closure was safe and effective. The procedure 
did not affect arrhythmias observed in Holter ECG moni-
toring of the study patients, neither atrial fibrillation nor 
atrioventricular conduction disturbances were found. All 
PFOs were successfully closed, as seen during follow-up 
TTEs. The results of this study provide additional evidence 
that the current scientific consensus on PFO closure is 
valid. The procedure has a low risk of complications if 
performed in carefully selected patients by an adequately 
trained operator in an experienced centre.
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Streszczenie
Wstęp. Przetrwały otwór owalny (PFO) to częsta anomalia, występująca u około 25% populacji. Zabieg przezskórnego 
zamykania PFO zaleca się u wybranych pacjentów w celu zapobiegania nawrotom incydentów zakrzepowo-zatorowych. 
Mimo że przezcewnikowe zamykanie PFO jest uznawane za zabieg bezpieczny, może być przyczyną potencjalnych 
powikłań, takich jak migotanie przedsionków (AF). Celem pracy była ocena występowania arytmii u pacjentów przed 
zabiegiem zamknięcia PFO i po nim.
Materiał i metody. Retrospektywnie przeanalizowano dokumentację medyczną 45 pacjentów (mediana wieku 45 [za-
kres międzykwartylowy 35–61] lat; 80% kobiet), którzy przebyli zabieg przezskórnego zamknięcia PFO. Dwudziestoczte-
rogodzinne monitorowanie elektrokardiograficzne (EKG) metodą Holtera wykonano przed zabiegiem oraz 3 miesiące po 
zabiegu u 21 pacjentów (mediana wieku 49 [38–65] lat; 81% kobiet), jednak dane o rytmie prowadzącym były dostępne 
w odniesieniu do wszystkich 45 pacjentów.
Wyniki. Nie wykazano istotnych statystycznie różnic w zakresie maksymalnej i minimalnej częstości pracy serca, liczby 
nadkomorowych i komorowych pobudzeń dodatkowych, liczby pauz, liczby epizodów częstoskurczów nadkomorowych 
lub komorowych u pacjentów przed zabiegiem zamknięcia PFO i po tym zabiegu. Mediana średnich częstości pracy 
serca była istotnie wyższa przed zabiegiem (70 [67–78]/min vs. 69 [62–77]/min; p = 0,03). U jednej osoby spośród 
45 pacjentów stwierdzano napadowe AF przed zabiegiem. Podczas 3-miesięcznej obserwacji nie wykryto żadnego 
epizodu AF.
Wnioski. Zabieg przezcewnikowego zamknięcia PFO nie wpłynął na arytmie obserwowane w 24-godzinnym monito-
rowaniu EKG metodą Holtera w badanej grupie. Zabieg cechuje się niskim ryzykiem powikłań, o ile jest wykonywany 
u właściwie zakwalifikowanych pacjentów, przez odpowiednio wyszkolonego operatora i w ośrodku z doświadczonym 
personelem.
Słowa kluczowe: przetrwały otwór owalny, przezskórne zamknięcie, udar kryptogenny, arytmia, migotanie 
przedsionków
Folia Cardiologica 2021; 16, 1: 8–15
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